Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$7.14 - $8.53 $749,700 - $895,649
-105,000 Reduced 70.0%
45,000 $324,000
Q3 2022

Nov 14, 2022

BUY
$8.95 - $12.0 $1.34 Million - $1.8 Million
150,000 New
150,000 $1.39 Million

Others Institutions Holding BLU

# of Institutions
1
Shares Held
128K
Call Options Held
0
Put Options Held
0

About BELLUS Health Inc.


  • Ticker BLU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,793,000
  • Description
  • BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...
More about BLU
Track This Portfolio

Track Lion Point Capital, LP Portfolio

Follow Lion Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Lion Point Capital, LP with notifications on news.